Irreverible corneal decompenation in patient treated with topical dorzolamide Original Reearch Article

Purpoe: To decribe irreverible corneal decompenation after topical dorzolamide hydrochloride (Truopt; Merck and Co, Inc, Wet Point, Pennylvania) therapy in nine patient who had hitorie conitent with corneal endothelial compromie. Method: Multicenter review of patient’ chart. Reult: Nine eye of nine patient developed overt corneal decompenation after tarting topical dorzolamide, a condition that did not reolve with drug ceation. Thi occurred after 3 to 20 week (mean, 7.8) of therapy. All nine patient had undergone intraocular urgery. Eight patient had undergone cataract urgery; three were aphakic and three had poterior chamber intraocular lene. Two patient had anterior chamber intraocular lene and alo had undergone trabeculectomie. Four patient had undergone penetrating keratoplatie, each cae complicated by epiode of corneal allograft rejection that were uccefully treated. Two patient had aymptomatic Fuch endothelial dytrophy. even patient have ince undergone ucceful penetrating keratoplatie. Concluion: The report ugget that dorzolamide can caue irreverible corneal edema in a ubet of glaucoma patient with endothelial compromie. The finding ugget a rationale for reearch into the long-term effect of dorzolamide on the corneal endothelium.